	US 11,732,303 B2
	Prognostic marker for myeloproliferative neoplasms
Christine Bellane-Chantelot, Nogent sur Marne (FR); Isabelle Plo, Etampes (FR); William Vainchenker, Paris (FR); Cécile Saint-Martin, Paris (FR); Antonio D Di Stefano, Rungis (FR); and Joseph Saliba, Paris (FR)
Assigned to Institut Gustave-Roussy, Villejuif (FR)
Appl. No. 15/739,454
Filed by Institut Gustave-Roussy, Villejuif (FR)
PCT Filed Jun. 24, 2016, PCT No. PCT/EP2016/064754 § 371(c)(1), (2) Date Sep. 7, 2018, PCT Pub. No. WO2016/207405, PCT Pub. Date Dec. 29, 2016.
Claims priority of application No. 15306001 (EP), filed on Jun. 25, 2015.
Prior Publication US 2020/0239961 A1, Jul. 30, 2020
Int. Cl. C12Q 1/6886 (2018.01); G01N 33/574 (2006.01)

CPC C12Q 1/6886 (2013.01) [G01N 33/57426 (2013.01); C12Q 2600/156 (2013.01)]

12 Claims

1. An in vitro method comprising:

a) obtaining a biological sample of a human subject suffering from essential thrombocythemia,

b) analyzing the copy number of a genomic region having at least 20 consecutive nucleotides of SEQ ID NO:1 in said biological sample, to detect that at least two copy numbers are present in said biological sample.